Tandem Diabetes Care (TNDM) Cash & Equivalents (2013 - 2026)

Tandem Diabetes Care's Cash & Equivalents history runs 14 years deep, the most recent figure standing at $179.3 million for Q1 2026.

• Quarterly Cash & Equivalents rose 234.72% year-over-year to $179.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $179.3 million (up 234.72% YoY) and the FY2025 annual result came in at $90.6 million, up 30.91% from the prior year.
• Cash & Equivalents was $179.3 million for Q1 2026 at Tandem Diabetes Care, up from $90.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $179.3 million in Q1 2026 and bottomed at $47.7 million in Q2 2024.
• A 5-year average of $94.5 million and a median of $90.6 million in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents tumbled 65.88% — and 2026, when it surged 234.72%.
• Tandem Diabetes Care's Cash & Equivalents stood at $172.5 million in 2022, then tumbled by 65.88% to $58.9 million in 2023, then grew by 17.61% to $69.2 million in 2024, then surged by 30.91% to $90.6 million in 2025, then jumped by 97.86% to $179.3 million in 2026.
• Business Quant data shows TNDM's Cash & Equivalents at $179.3 million in Q1 2026, $90.6 million in Q4 2025, and $91.9 million in Q3 2025.